Dr. Heather Kay Webb Hsu
Chief Scientific Officer, Inipharm
Heather Kay Webb Hsu is the Chief Scientific Officer for Inipharm, a startup pharmaceutical company focused on discovery of drugs targeting genetically-defined mechanisms for the treatment of chronic liver disease. She comes to this position with 23 years of pharmaceutical/biotech industry experience with research, nonclinical development and clinical pharmacology. She has built, participated in and led teams of skilled professionals that have brought multiple drugs from discovery through to clinical proof of concept. Including participating in regulatory filings and communication for drugs in clinical development through to approval. After completing her PhD at the University of Michigan, her drug development work includes programs including but not limited to oncology, inflammatory and cardiometabolic diseases at companies including Johnson and Johnson and Gilead Sciences as well as small companies.
The Human Touch: How Liver-on-a-Chip Addresses the Unmet Needs of Liver Disease Research
• Liver disease progresses from a dysregulation of metabolism
• Lipid metabolism differs between mice and men and the impact this has on drug development
• Primary human NASH models can evaluate drugs that target metabolism
• NASH models allow the quantitation of lipid droplets, metabolism and fibrosis